

## ERYTECH provides financial update for Q1 2013

**Lyon (France), June 3 2013** – ERYTECH, (NYSE Euronext Paris : FR0011471135 - ERYP) a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announced today its cash position and its revenues for first quarter 2013.

On March 31 2013, ERYTECH's cash and cash equivalents amounted to € 4.7 million. It is important to note that this amount does not include € 16.7 million raised by ERYTECH during its initial public offering in April 2013.

During the first quarter of fiscal year 2013, ERYTECH did not report any income from activities.

These results are in line with the expectations and the strategy of the company which in 2013 remains totally focused on the clinical development of its innovative treatments for acute leukemia and other oncology indications in Europe and in the United States.

As a reminder, GRASPA<sup>®</sup>, ERYTECH's lead product is currently in the final phase of clinical development for Acute Lymphoblastic Leukemia in Europe and is the object of a licensing and distribution agreement in Europe with Orphan Europe (Recordati Group), a major actor in orphan diseases.

### Next scheduled events:

**Release of Second quarter 2013 sales:** Thursday July 18 2013 (after market)

ERYTECH also takes part in:

- **Jefferies' Annual Healthcare Conference** on June 6 2013, in New-York (USA)
- **BOSTON CEO Event** on June 11 and 12 2013, in Boston (USA)

**About ERYTECH:** [www.erytech.com](http://www.erytech.com)

Created in Lyon in 2004, ERYTECH is a French biopharmaceuticals company that opens new prospects for cancer patients, particularly those with acute leukaemia. By encapsulating the asparaginase enzyme in red blood cells, ERYTECH has developed GRASPA<sup>®</sup>, an original and effective treatment that targets leukaemia cells through "starvation" while significantly reducing the side effects for patients. GRASPA<sup>®</sup> is currently completing Phase III clinical development in Acute Lymphoblastic Leukemia (ALL) and is in Phase II clinical trial in Acute Myeloid Leukemia (AML). ERYTECH has concluded distribution partnership agreements for Europe with the Recordati - Orphan Europe group, and with TEVA for Israël. In the United States, ERYTECH is launching a Phase I clinical trial in ALL, after having received approval from the US FDA.

*ERYTECH is listed on NYSE Euronext regulated market in Paris. (Code ISIN : FR0011471135, mnémo : ERYP) and is part of CAC Healthcare, CAC Pharm. & Bio et Next Biotech indexes.*

## CONTACTS

### **ERYTECH**

**Gil Beyen**

*Chairman and CEO*

**Pierre-Olivier Goineau**

*Vice President and COO*

Tel : +33 4 78 74 44 38

[investors@erytech.com](mailto:investors@erytech.com)

### **NewCap.**

Investor and press relations

**Julien Perez / Emmanuel Huynh**

Tél : +33 1 44 71 98 52

[erytech@newcap.fr](mailto:erytech@newcap.fr)

